Navigation Links
Albuferon in Medical News

HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatit...

HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...Drugs in Select Countries (includes corresponding Graph/Chart) II-3 albuferon - Rising Above the Standards II-4 Viramidine - Next-Generation Ribaviri...s with GI-5005 II-57 Human Genome Gets Encouraging Interim Results with albuferon II-58 Intarcia Releases Study Results of Omega Interferon II-58 Nau...

Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)

... of required injections. As a result, the value of HGSI shares was reduced by 57% the day the study data was released. I can't help but wonder how albuferon might have performed in combination with our Hemopurifier(R)? Regardless, a drug candidate wishing to supplant SOC therapy in the market will need to...

Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors

...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE HARBOR STATEMENT This announcement contains forward-looking statements within ...
Albuferon in Medical Technology

Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon

- Albuferon 900-mcg dosed every two weeks achieved an SVR rate at least comparable to Pegasys dosed every week (ITT analysis), with more favorable quality-of-life scores - ROCKVILLE, Md., June 07, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the top-line final results...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the submission of global marketing applications is expected in fall 2009. BENLYSTA successfully met its pr...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE ...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...as many injections, in two pivotal Phase 3 trials, albuferon (albinterferon alfa-2b) met the primary efficacy e...eron alfa-2a) - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve... the half-life of the therapeutic proteins. albuferon is being developed by HGS and Novartis for the tre...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... - 900-mcg albuferon (albinterferon alfa-2b) dosed every two weeks met ...c hepatitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve...Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

...e reported our company's first Phase 3 results for albuferon in chronic hepatitis C, and the data were positive. We will have results of the second albuferon Phase 3 trial in March 2009, and the results of ou...or 2008 included $35.4 million recognized from the albuferon agreement with Novartis, and $6.5 million in reven...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile

...an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/ . HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking st...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... that the results of ACHIEVE 2/3 demonstrated that albuferon (albinterferon alfa-2b) met its primary endpoint o...ic response was comparable for the 900-mcg dose of albuferon administered every two weeks, vs. the standard 180...e. The results of ACHIEVE 1, the Phase 3 trial of albuferon in genotype 1 chronic hepatitis C, are expected in...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

...ted from spam bots, you need JavaScript enabled to view it or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...
Albuferon in Biological Technology

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has successfully completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. BENLYSTA has successfully m...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

...cted by Novartis evaluating safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...on a weekly basis. A monthly dosing schedule with albuferon may well result in more patients choosing to be tr...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... - Positive results for second Phase 3 trial of albuferon (R) in chronic hepatitis C; global marketing ap...ved our first product sales with ABthrax, and both albuferon and LymphoStat-B(R) continued to make excellent pr...e results from the second of two pivotal trials of albuferon in chronic hepatitis C, and we plan global marketi...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. HGS ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon successfully met its primary endpoint in the first of two Phase 3 trials in chronic hepatitis C; results of the second albuferon Phase 3 trial are expected in March 2009. Two Phase 3 clinical trials of L...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

...ted by Novartis to evaluate safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...ctions." In December 2008, HGS announced that albuferon met its primary endpoint of non-inferiority to peg...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... - albuferon (albinterferon alfa-2b) met its primary endpoint o...patitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious adverse events, se...gasys) in ACHIEVE 2/3, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

... are on track to report our first Phase 3 data for albuferon in December 2008. We are on track to report our fi...emains on track to have the first Phase 3 data for albuferon - from the ACHIEVE 2/3 trial - in December 2008. A...nsion 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sc...
Other Tags
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an interview ... role as a kicking coach, his kicking business, and on ... retired NFL kicker Michael Husted author of HustedKicking.com. , "Anthony ... one of the top pro free agent kickers out there,” ... at our 2014 Pro Camp and I was impressed with ...
(Date:9/2/2014)... 2014: The fact that mechanical heart valves increase risks ... from the ROPAC registry presented for the first time ... Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall ... 1.4% of pregnant women with a mechanical heart valve ... The Registry Of Pregnancy And Cardiac disease (ROPAC) is ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 “Harmonicas ... about a decade, primarily to help people with ... there are three developed systems,” says Dana Keller, ... substantively differ, the goals are much the same ... of some type of harmonica.” , The three ...
(Date:9/2/2014)... Fast hosting is a great choice for webmasters to ... hosting suppliers and announced that Arvixe, Bluehost and JustHost ... is hard to find a good fast hosting supplier. ... features, uptime, server speed and customer support. People can ... manager of Top10BestSEOHosting.com says. , Arvixe has a world-class ...
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2
(Date:8/29/2014)... and number of connections in transcription factor networks (TFNs) ... a study published in PLOS Computational Biology ... signature contributes to a network,s resilience against mutations. ... assortativity of TFN models has a greater effect on ... of assortativity," said Dov A. Pechenick, PhD, lead author ...
(Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
(Date:8/28/2014)... marine protected areas is needed to protect fish species ... from the Wildlife Conservation Society and other organizations, previous ... largest numbers of species, often at the expense of ... , Many vital ecological functions of ocean ... food for millions of people. This study uncovers ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
Other Contents